Patents by Inventor Robert Melder
Robert Melder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230181251Abstract: Methods for treating a patient using therapeutic renal neuromodulation and associated devices, system, and methods are disclosed herein. One aspect of the present technology is directed to neuromodulating nerve tissue in selected anatomical regions. In one embodiment, the method can include intravascularly advancing an elongate shaft of a catheter to renal vasculature of a human patient and locating a first neuromodulation element of the catheter within a distalmost portion of a main renal artery. The method includes locating a second neuromodulation element of the catheter within a branch vessel of the renal artery distal to a bifurcation at a distal end of the main renal artery. Neuromodulation of the nerve tissue surrounding the selected anatomical treatment locations can inhibit sympathetic neural activity in nerves proximate a portion of a renal artery and/or a renal branch artery proximate a renal parenchyma.Type: ApplicationFiled: February 2, 2023Publication date: June 15, 2023Inventors: Robert Melder, Martin Rothman, Stefan Tunev
-
Publication number: 20220280230Abstract: Methods for treating a human patient diagnosed with cancer with therapeutic neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological processes associated with the progression of cancer. One aspect of the present technology is directed to methods that attenuate neural traffic along target sympathetic nerves innervating tissue proximate a primary malignant tumor. Other aspects are directed to methods that at least partially inhibit sympathetic neural activity in a renal nerve of a patient diagnosed with cancer or who has a high risk of developing cancer. Targeted sympathetic nerve activity can be attenuated to improve a measurable physiological parameter corresponding to the progression of cancer in the patient. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g.Type: ApplicationFiled: May 25, 2022Publication date: September 8, 2022Inventors: Garrett Pilcher, Robert Melder
-
Patent number: 11350992Abstract: Methods for treating a human patient diagnosed with cancer with therapeutic neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological processes associated with the progression of cancer. One aspect of the present technology is directed to methods that attenuate neural traffic along target sympathetic nerves innervating tissue proximate a primary malignant tumor. Other aspects are directed to methods that at least partially inhibit sympathetic neural activity in a renal nerve of a patient diagnosed with cancer or who has a high risk of developing cancer. Targeted sympathetic nerve activity can be attenuated to improve a measurable physiological parameter corresponding to the progression of cancer in the patient. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g.Type: GrantFiled: July 31, 2020Date of Patent: June 7, 2022Assignee: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.Inventors: Garrett Pilcher, Robert Melder
-
Publication number: 20200360081Abstract: Methods for treating a human patient diagnosed with cancer with therapeutic neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological processes associated with the progression of cancer. One aspect of the present technology is directed to methods that attenuate neural traffic along target sympathetic nerves innervating tissue proximate a primary malignant tumor. Other aspects are directed to methods that at least partially inhibit sympathetic neural activity in a renal nerve of a patient diagnosed with cancer or who has a high risk of developing cancer. Targeted sympathetic nerve activity can be attenuated to improve a measurable physiological parameter corresponding to the progression of cancer in the patient. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g.Type: ApplicationFiled: July 31, 2020Publication date: November 19, 2020Inventors: Garrett Pilcher, Robert Melder
-
Publication number: 20200324092Abstract: A balloon catheter includes an inflatable balloon defining an inner and an outer surface. A first biocompatible layer that includes hyaluronic acid is releasably disposed on the outer surface of the balloon. A second drug containing layer is disposed on the first biocompatible layer. The second drug containing layer includes paclitaxel and urea.Type: ApplicationFiled: June 26, 2020Publication date: October 15, 2020Inventors: Robert Melder, John Kantor
-
Patent number: 10736692Abstract: Methods for treating a human patient diagnosed with cancer with therapeutic neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological processes associated with the progression of cancer. One aspect of the present technology is directed to methods that attenuate neural traffic along target sympathetic nerves innervating tissue proximate a primary malignant tumor. Other aspects are directed to methods that at least partially inhibit sympathetic neural activity in a renal nerve of a patient diagnosed with cancer or who has a high risk of developing cancer. Targeted sympathetic nerve activity can be attenuated to improve a measurable physiological parameter corresponding to the progression of cancer in the patient. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g.Type: GrantFiled: June 27, 2016Date of Patent: August 11, 2020Assignee: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.Inventors: Garrett Pilcher, Robert Melder
-
Patent number: 10695542Abstract: A balloon catheter includes an inflatable balloon defining an inner and an outer surface. A first biocompatible layer that includes hyaluronic acid is releasably disposed on the outer surface of the balloon. A second drug containing layer is disposed on the first biocompatible layer. The second drug containing layer includes paclitaxel and urea.Type: GrantFiled: March 22, 2017Date of Patent: June 30, 2020Assignee: Medtronic Vascular, Inc.Inventors: Robert Melder, John Kantor
-
Publication number: 20190231420Abstract: Methods for treating a patient using therapeutic renal neuromodulation and associated devices, system, and methods are disclosed herein. One aspect of the present technology is directed to neuromodulating nerve tissue in selected anatomical regions. In one embodiment, the method can include intravascularly advancing an elongate shaft of a catheter to renal vasculature of a human patient and locating a first neuromodulation element of the catheter within a distalmost portion of a main renal artery. The method includes locating a second neuromodulation element of the catheter within a branch vessel of the renal artery distal to a bifurcation at a distal end of the main renal artery. Neuromodulation of the nerve tissue surrounding the selected anatomical treatment locations can inhibit sympathetic neural activity in nerves proximate a portion of a renal artery and/or a renal branch artery proximate a renal parenchyma.Type: ApplicationFiled: February 8, 2019Publication date: August 1, 2019Inventors: Robert Melder, Martin Rothman, Stefan Tunev
-
Publication number: 20170312021Abstract: Methods for treating a human patient diagnosed with cancer with therapeutic neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological processes associated with the progression of cancer. One aspect of the present technology is directed to methods that attenuate neural traffic along target sympathetic nerves innervating tissue proximate a primary malignant tumor. Other aspects are directed to methods that at least partially inhibit sympathetic neural activity in a renal nerve of a patient diagnosed with cancer or who has a high risk of developing cancer. Targeted sympathetic nerve activity can be attenuated to improve a measurable physiological parameter corresponding to the progression of cancer in the patient. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g.Type: ApplicationFiled: June 27, 2016Publication date: November 2, 2017Inventors: Garrett Pilcher, Robert Melder
-
Publication number: 20170281912Abstract: A balloon catheter includes an inflatable balloon defining an inner and an outer surface. A first biocompatible layer that includes hyaluronic acid is releasably disposed on the outer surface of the balloon. A second drug containing layer is disposed on the first biocompatible layer. The second drug containing layer includes paclitaxel and urea.Type: ApplicationFiled: March 22, 2017Publication date: October 5, 2017Inventors: Robert Melder, John Kantor
-
Patent number: 9615948Abstract: The drug eluting folded stent and a stent delivery system, which includes a stent having a plurality of struts interconnected to form a tubular body. At least one of the struts includes a U-shaped strut having in cross-section a first leg, a second leg, and a closed end connecting the first leg and the second leg, wherein the first leg, the second leg, and the closed end define a recess having a drug release opening opposite the closed end; and a drug coating disposed on the first leg, the second leg, and the closed end within the recess. The drug release opening is sized to release a drug from the drug coating at a predetermined drug elution rate.Type: GrantFiled: April 26, 2010Date of Patent: April 11, 2017Assignee: Medtronic Vascular, Inc.Inventor: Robert Melder
-
Publication number: 20150327924Abstract: Methods for treating a patient using therapeutic renal neuromodulation and associated devices, system, and methods are disclosed herein. One aspect of the present technology is directed to neuromodulating nerve tissue in selected anatomical regions. In one embodiment, the method can include intravascularly advancing an elongate shaft of a catheter to renal vasculature of a human patient and locating a first neuromodulation element of the catheter within a distalmost portion of a main renal artery. The method includes locating a second neuromodulation element of the catheter within a branch vessel of the renal artery distal to a bifurcation at a distal end of the main renal artery. Neuromodulation of the nerve tissue surrounding the selected anatomical treatment locations can inhibit sympathetic neural activity in nerves proximate a portion of a renal artery and/or a renal branch artery proximate a renal parenchyma.Type: ApplicationFiled: May 15, 2015Publication date: November 19, 2015Inventors: Robert Melder, Martin Rothman, Stefan Tunev
-
Patent number: 8678046Abstract: Methods and apparatus are disclosed for loading a therapeutic substance or drug within a lumenal space of a hollow wire having a plurality of side openings along a length thereof that forms a hollow drug-eluting stent with a plurality of side drug delivery openings. Loading a drug within the lumenal space of the hollow stent includes a drug filling step, in which the drug is mixed with a solvent or dispersion medium. The lumenal space may be filled with the drug solution or suspension in a reverse fill process and/or a forward fill process. After the drug filling step, a solvent or dispersion medium extracting step is performed to extract the solvent or dispersion medium from within the lumenal space such that only the drug remains within the hollow stent. A stent cleaning step may be performed to an exterior surface of the hollow stent.Type: GrantFiled: September 17, 2010Date of Patent: March 25, 2014Assignee: Medtronic Vascular, Inc.Inventors: Robert Melder, Barry Wohl
-
Publication number: 20120067454Abstract: Methods and apparatus are disclosed for loading a therapeutic substance or drug within a lumenal space of a hollow wire having a plurality of side openings along a length thereof that forms a hollow drug-eluting stent with a plurality of side drug delivery openings. Loading a drug within the lumenal space of the hollow stent includes a drug filling step, in which the drug is mixed with a solvent or dispersion medium. The lumenal space may be filled with the drug solution or suspension in a reverse fill process and/or a forward fill process. After the drug filling step, a solvent or dispersion medium extracting step is performed to extract the solvent or dispersion medium from within the lumenal space such that only the drug remains within the hollow stent. A stent cleaning step may be performed to an exterior surface of the hollow stent.Type: ApplicationFiled: September 17, 2010Publication date: March 22, 2012Applicant: Medtronic Vascular, Inc.Inventor: Robert Melder
-
Publication number: 20100261737Abstract: A combined therapy for treatment of a patient having erectile dysfunction at least in part caused by vascular disease within a pelvic vessel is disclosed that includes placement of a stent within a stenosed region of the pelvic vessel in conjunction with the administration of a drug for treatment of erectile dysfunction.Type: ApplicationFiled: April 10, 2009Publication date: October 14, 2010Applicant: Medtronic Vascular, Inc.Inventors: Garrett Pilcher, Mark J. Dolan, Robert Melder, Christopher Bingham
-
Patent number: 7753962Abstract: Disclosed are medical devices having textured surfaces and biocompatible coatings disposed thereon. The textured surfaces allow for durable coatings to be applied to the medical device without a previous pre-coating having been applied. The biocompatible coating can further comprise a bioactive agent.Type: GrantFiled: January 30, 2007Date of Patent: July 13, 2010Assignee: Medtronic Vascular, Inc.Inventor: Robert Melder
-
Publication number: 20090317394Abstract: The present invention is directed to VEGF-2 polynucleotides and polypeptides and methods of using such polynucleotides and polypeptides. In particular, provided are methods of treating retinal disorders with VEGF-2 polynucleotides and polypeptides.Type: ApplicationFiled: October 24, 2008Publication date: December 24, 2009Inventors: RALPH ALDERSON, Robert Melder, Viktor Roschke, Steven M. Ruben, Craig A. Rosen
-
Patent number: 7524501Abstract: The present invention is directed to VEGF-2 polynucleotides and polypeptides and methods of using such polynucleotides and polypeptides. In particular, provided are methods of treating retinal disorders with VEGF-2 polynucleotides and polypeptides.Type: GrantFiled: March 14, 2005Date of Patent: April 28, 2009Assignee: Human Genome Sciences, Inc.Inventors: Ralph Alderson, Robert Melder, Viktor Roschke, Steven M. Ruben, Craig A. Rosen
-
Patent number: 7223724Abstract: The present invention is directed to VEGF-2 polynucleotides and polypeptides and methods of using such polynucleotides and polypeptides. In particular, provided are methods of treating retinal disorders with VEGF-2 polynucleotides and polypeptides.Type: GrantFiled: February 7, 2000Date of Patent: May 29, 2007Assignee: Human Genome Sciences, Inc.Inventors: Ralph Alderson, Robert Melder, Viktor Roschke, Steven M. Ruben, Craig A. Rosen
-
Patent number: 7045496Abstract: The present invention is directed to VEGF-2 polynucleotides and polypeptides and methods of using such polynucleotides and polypeptides. In particular, provided are methods of treating retinal disorders with VEGF-2 polynucleotides and polypeptides.Type: GrantFiled: February 7, 2000Date of Patent: May 16, 2006Assignee: Human Genome Sciences, Inc.Inventors: Ralph Alderson, Robert Melder, Viktor Roschke, Steven M. Ruben, Craig A. Rosen